Norvasc
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Norvasc"
.

content
Amlodipine
Systematic (IUPAC) name
3-ethyl-5-methyl-2-(2-aminoethoxymethyl)-4-(2-
chlorophenyl)-1,4-dihydro-6-methyl-3,5- pyridinedicarboxylate
Identifiers
CAS number 88150-42-9
ATC code C08CA01
PubChem 2162
DrugBank APRD00520
ChemSpider 2077
Chemical data
Formula C20H25ClN2O5 
Mol. mass 408.879 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 64 to 90%
Metabolism Hepatic
Half life 30 to 50 hours
Excretion Renal
Therapeutic considerations
Pregnancy cat.

C(AU) C(US)

Legal status

POM(UK) -only(US)

Routes Oral (tablets)

Amlodipine (as besylate, mesylate or maleate) is a long-acting calcium channel blocker (dihydropyridine) used as an anti-hypertensive and in the treatment of angina. Like other calcium channel blockers, amlodipine acts by relaxing the smooth muscle in the arterial wall, decreasing peripheral resistance and hence reducing blood pressure; in angina it increases blood flow to the heart muscle.

Amlodipine is marketed as Dailyvasc in the Philippines by Xeno Pharmaceuticals, and by Pfizer as Norvasc in North America and Australia and as Istin in the United Kingdom. Generic brands (sold under names such as Perivasc in Australia) are also available.

Contents

Indications

Cautions

Contraindications

Side effects

Some side effects1 of the use of amlodipine may be:

Dose

Salts

In the United Kingdom tablets of amlodipine from different suppliers may contain different salts. The strength of the tablets is expressed in terms of amlodipine base, i.e., without the salt. Tablets containing different salts are therefore considered interchangeable.

Drug Metabolism and Excretion

Amlodipine is almost entirely metabolised to inactive metabolites. Ten per cent of the parent substance and 60% of the metabolites are excreted in urine.

Patent loss

Pfizer patent protection on Norvasc lasted until 2007. A number of generic versions are now available. Total patent expiration occurred later in 2007.2

References

  1. ^ Source: Sandoz product information sheet
  2. ^ Kennedy, Val Brickates (2007-03-22). "Pfizer loses court ruling on Norvasc patent", MarketWatch. 

External links

© jGames.co.uk 2007 (some content from Wikipedia under GDL ) !-- ValueClick Media 468x60 and 728x90 Banner CODE for jgames.co.uk -->
Your Ad Here